ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

AstraZeneca And MRC Combine Libraries

by Lisa M. Jarvis
July 12, 2010 | APPEARED IN VOLUME 88, ISSUE 28

AstraZeneca and MRC Technology, the commercialization arm of the U.K.’s Medical Research Council, are teaming up to discover new medicines for a variety of diseases. The organizations will screen 100,000 compounds from AstraZeneca’s library and 50,000 compounds from the MRC collection against 10 biological targets. AstraZeneca has already selected five targets in cancer, cardiovascular disease, neuroscience, and infection. A joint review committee will determine whether to advance promising compounds yielded by the screens, but each organization will retain ownership of its compounds.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment